Fig. 4

Myeloid immune cell subsets differ significantly between the different versions of the MMTV-PyMT breast tumor model. Tumors from the autochthonous MMTV-PyMT model were harvested and single-cell suspensions were generated. Cells (1E6, 1E5, or 1E4) were injected into the mammary fat pad of FVB/NJ wild-type mice. When tumors reached 100 mm³, tumors were obtained and processed into a single-cell suspension for immunophenotyping by flow cytometry. a–d Analysis of cells subsets as a percent of myeloid cells (CD11b⁺) include a myeloid-derived suppressor cells (MDSC (GR1⁺)), b PD-L1⁺F4/80⁺, c PD-L1^– F4/80⁺, and d other CD11b⁺ populations; e Analysis of the myeloid cells subsets as a percent of viable cells include f analysis of PD-L1 expression on myeloid cells (CD11b⁺) and g cancer cells represented by CD45^-. h Analysis of the ratio of lymphocytes expressing PD-1. i Analysis of M1-like macrophage markers, CD40⁺, CD80⁺, and CD86⁺ and an M2-like macrophage marker, CD206⁺, as a ratio of total myeloid cells (CD11b⁺, top), and mature macrophages (F4/80⁺, bottom). Graphs show mean ± SEM from at least two independent experiments with at least three mice per group. Each data point represents an individual mouse. Unpaired two-tailed t test. *P<0.05, **P<0.01, ***P<0.001, and ****P<0.001